Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction
Keywords:
Sildenafil; Intraocular Pressure; Long-Term UseAbstract
Background and aim: Sildenafil is used to treat erectile dysfunction but it has association with some side effects. This study was conducted with the aim of investigating the effect of duration of taking sildenafil on intraocular pressure (IOP) in patients with erectile dysfunction.
Methods: The study population of this cross-sectional study were all males with erectile dysfunction referring to the urology clinic affiliated to Rafsanjan University of Medical Sciences (Kerman, Iran) over a one-year period (2015-2016) among whom 110 patients were included in the study. After medical examinations and required investigations, a weekly dose of 25-100mg sildenafil (50 mg per week on average) was prescribed for patients. IOP in these patients was measured by an ophthalmologist before, one month after and three months after taking medication respectively. Finally, data were analyzed by SPSS version 16 using repeated measures test.
Results: Mean IOP before taking medication as well as one month and three months after taking sildenafil was 14.88±1.3, 15±1.28 and 15±1.34 mmHg respectively. Analysis of results showed that the difference in IOP in various periods of measurement was significant (p<0.001). Mean IOP before taking sildenafil was significantly different from three months after taking it (p<0.001) and mean IOP one month after taking sildenafil was significantly different from three months after taking it (p=0.002).
Conclusion: Results of this study indicated that taking sildenafil for three months increased IOP. Although these changes may not be clinically significant.
References
Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. British journal of pharmacology. 2006;
Suppl 1: S252-7. doi: 10.1038/sj.bjp.0706495.
Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Drug Des Devel Ther. 2010; 4: 147-58. PMID: 20689641, PMCID: PMC2915539.
Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and
differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des. 2006; 12(27):
-65. doi: 10.2174/138161206778343118. PMID: 17017939.
Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in
the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007; 15(2): 76-86. doi:
1097/01.crd.0000233904.77128.49. PMID: 17303994.
Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. International
journal of impotence research. 2004; 16 Suppl 1: S11-4. doi: 10.1038/sj.ijir.3901208.
Gerometta R, Alvarez LJ, Candia OA. Effect of Sildenafil Citrate on Intraocular Pressure and Blood
Pressure in Human Volunteers. Exp Eye Res. 2011; 93(1): 103-7. doi: 10.1016/j. exer. 2011.05.010. PMID:
, PMCID: PMC3138881.
Moeini Moghaddam R, Shalizar Jalali A, Najafi GR, Behfar M. Protective effect of Sildenafil on
contralateral epididymal sperm concentration and motility following unilateral blunt testicular trauma in
pre-pubertal male mice. Journal of Shahrekord Uuniversity of Medical Sciences. 2015; 17(4): 11-6.
Akintunde JK, Ajiboye JA, Siemuri EO, Oyelowo SB, Sunday OJ, Abam EO, et al. Sub-chronic treatment
of sildernafil citrate (Viagra) on some enzymatic and nonenzymatic antioxidants in testes and brain of male
rats. J Pharm Drug Deliv Res. 2012; 1: 1-5. doi: 10.4172/2325-9604.1000105.
Hallowell L, Comerford KC. Nursing 2015 Drug Handbook. 35th ed. Wolters Kluwer Health. 2014.
Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM. Ocular safety of sildenafil citrate when
administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double
masked, placebo controlled trial and open label extension. BMJ. 2012; 344: e554. doi: 10.1136/bmj.e554.
PMID: 22354598, PMCID: PMC3283528.
Koksal M, Ozdemir H, Kargi S, Yesilli C, Tomac S, Mahmutyazicioglu K, et al. The effects of sildenafil on
ocular blood flow. Br J Ophthalmol. 2008; 92(4): 469-73. doi: 10.1136/bjo.2007.131789. PMID:
Kotikoski H, Vapaatalo H, Oksala O. Nitric oxide and cyclic GMP enhance aqueous humor outflow facility
in rabbits. Current eye research. 2003; 26(2): 119-23. doi: 10.1076/ceyr.26.2.119.14511. PMID: 12815531.
Kerr NM, Danesh-Meyer HV. Phosphodiesterase inhibitors and the eye. Clin Exp Ophthalmol. 2009; 37(5):
-23. doi: 10.1111/j.1442-9071.2009.02070.x. PMID: 19624350.
Gerometta R, Alvarez LJ, Candia OA. Effects of Sildenafil and Tadalafil on Intraocular Pressure in Sheep:
Implications for Aqueous Humor Dynamics. Invest Ophthalmol Vis Sci. 2010; 51(6): 3139-44. doi:
1167/iovs.09-4862. PMID: 20089876, PMCID: PMC2891473.
Grunwald JE, Jacob SS, Siu K, Piltz J, Dupont J. Acute effects of sldenafil ctrate (Viagra) on intraocular
pressure in open-angle glaucoma. Am J Ophthalmol. 2001; 132(6): 872-4. doi: 10.1016/S0002- 9394(01)01268-5. PMID: 11730651.
Ermis SS, Inan UU, Samli M, Ozturk F. Acute effects of sildenafil on Humphrey visual field and
intraocular pressure. Int Ophthalmol. 2004; 25(2): 69-72. PMID: 15290883.
Yajima T, Yajima Y, Koppiker N, Grunwald JE, Laties AM. No clinically important effects on intraocular
pressure after short-term administration of sildenafil citrate (Viagra). Am J Ophthalmol. 2000; 129(5): 675- 6. doi: 10.1016/j.exer.2011.05.010. PMID: 10844068.
Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, et al. Reduction in intraocular
pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012; 119(9):
-31. doi: 10.1016/j.ophtha.2012.02.050. PMID: 22608478, PMCID: PMC3426647.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
